The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Health-related quality of life as a marker of treatment benefit with nivolumab in platinum-refractory patients with metastatic or unresectable urothelial carcinoma from CheckMate 275.
 
Andrea Necchi
Consulting or Advisory Role - AstraZeneca; Bayer; Merck Sharp & Dohme; Roche
Research Funding - Amgen (Inst); AstraZeneca (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Pierre Fabre; Roche
 
Marc-Oliver Grimm
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Hexal; Janssen-Cilag; Jenapharm; Pfizer; Pierre Fabre; Sanofi; Teva
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Pfizer; Sanofi
Research Funding - Bristol-Myers Squibb; Novartis
 
Margitta Retz
Consulting or Advisory Role - Bristol-Myers Squibb; Roche
 
Jose Angel Arranz Arija
Honoraria - Astellas Pharma; Novartis; Pfizer; Pierre Fabre
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen-Cilag; Novartis; Pfizer; Sanofi
Research Funding - GlaxoSmithKline (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Astellas Pharma
 
Sergio Bracarda
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; EUSA Pharma; Genentech; Ipsen; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Novartis
 
Jens Bedke
Honoraria - Novartis; Pfizer
Consulting or Advisory Role - Bayer; Eisai; EUSA Pharma; Nektar; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb; Immatics; Novartis; Roche
Travel, Accommodations, Expenses - Bayer
 
Ari David Baron
Speakers' Bureau - Bristol-Myers Squibb; Genentech; Lilly; Merck
Research Funding - Bristol-Myers Squibb; Genentech; Merck
 
Padmanee Sharma
Stock and Other Ownership Interests - Evelo Therapeutics; Jounce Therapeutics; Jounce Therapeutics; Jounce Therapeutics (I); Kite, a Gilead company; Kite, a Gilead company; Kite, a Gilead company (I); Neon Therapeutics; Neon Therapeutics (I)
Consulting or Advisory Role - Amgen; Amgen (I); AstraZeneca; AstraZeneca (I); Bristol-Myers Squibb; Bristol-Myers Squibb (I); Constellation Pharmaceuticals; Constellation Pharmaceuticals (I); EMD Serono; EMD Serono (I); Evelo Therapeutics; Evelo Therapeutics (I); GlaxoSmithKline; GlaxoSmithKline (I); Jounce Therapeutics; Jounce Therapeutics (I); Kite, a Gilead company; Kite, a Gilead company (I); Neon Therapeutics; Neon Therapeutics (I)
Patents, Royalties, Other Intellectual Property - Own patent licensed to Jounce; Own patents licensed to BMS, Jounce & Merck (I)
 
Matt D. Galsky
Stock and Other Ownership Interests - Dual Therapeutics
Consulting or Advisory Role - Astellas Pharma; BioMotiv; Dendreon; Genentech; GlaxoSmithKline; Janssen; Lilly; Merck
Research Funding - Bristol-Myers Squibb (Inst); Dendreon (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
Travel, Accommodations, Expenses - Astellas Pharma; BioMotiv; Dendreon; Merck
 
Daniel A. Vaena
Research Funding - Acerta Pharma (Inst); Argos Therapeutics (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Roche/Genentech (Inst); Tekmira (Inst); TRACON Pharma (Inst)
 
Ewa Kalinka-Warzocha
Honoraria - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD; Novartis; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD; Novartis; Roche
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb
 
Magdalena Cwikiel
No Relationships to Disclose
 
Sumanta K. Pal
Honoraria - Astellas Pharma; Medivation; Novartis
Consulting or Advisory Role - Astellas Pharma; Aveo; Bristol-Myers Squibb; Exelixis; Genentech; Myriad Pharmaceuticals; Novartis; Pfizer
Research Funding - Medivation
 
Rafael Morales
No Relationships to Disclose
 
Fiona Taylor
Consulting or Advisory Role - Bristol-Myers Squibb (Inst)
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Kyna McCullough Gooden
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Elizabeth R. Plimack
Consulting or Advisory Role - Acceleron Pharma; Acceleron Pharma; AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech/Roche; Lilly; Novartis; Synergene
Research Funding - Acceleron Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - U.S. Patent No.: 14/588,503, Filed 1/2/2015. (Inst)